C4X Discovery
C4X Discovery (C4XD) is a UK drug discovery company developing small molecule drug candidates using its proprietary computational and structural chemistry platform.
It applies enhanced candidate molecule design and patient stratification capabilities to generate drug candidates across immuno-inflammatory disease areas.
It maintains a portfolio spanning early-stage target opportunities to late-stage programmes, with multiple candidates partnered with pharmaceutical companies.
C4XD is privately held following its April 2024 AIM delisting. Its registered office moved from Manchester to Leeds in April 2026.
Latest News
C4X Discovery Shows In Vivo Proof of Concept for Oral PAD4 Inhibitor
C4X Discovery has established in vivo proof of concept for its oral PAD4 inhibitor, with a lead compound matching the activity of the anti-TNF biologic etanercept in a mouse model of rheumatoid arthritis at 10mg/kg. The company plans to continue partnering discussions for the programme during the rest of 2026.
C4X Discovery receives $13m AstraZeneca clinical milestone payment
C4X Discovery will receive a $13 million milestone payment from AstraZeneca, triggered by the entry of its licensed oral NRF2 activator programme (AZD4916) into a Phase I clinical trial. Under the 2022 licensing agreement, C4XD is potentially eligible for up to $400 million in preclinical, development and commercial milestones plus tiered royalties on future sales; AZD4916 is being developed for inflammatory and respiratory diseases.